Navigation Links
Gloucester Pharmaceuticals Receives Fast Track Designation for,Romidepsin in Peripheral T-Cell Lymphoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2007 - Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its novel histone deacetylase inhibitor, romidepsin, for the monotherapy of previously treated peripheral T-cell lymphoma (PTCL). The Company had previously announced that it has reached an agreement with the FDA under the FDA's Special Protocol Assessment (SPA) process for the design of its registration-directed trial of romidepsin in patients with PTCL, and that it has received Orphan Drug Status covering this indication in both the United States and Europe.

"The receipt of Fast Track Designation for PTCL is an important component of our overall product development strategy for romidepsin," commented John McBride, Executive Vice President and Chief Operating Officer at Gloucester. "We now are extremely well positioned to move forward with clinical development of romidepsin for PTCL, having previously secured Orphan Drug Designation and finalized a Special Protocol Assessment with the FDA for this indication. As a novel agent in a new class of drugs, histone deacetylase inhibitors, we believe romidepsin has significant potential as a treatment for a variety of hematological cancers as well as solid tumors," he concluded.

At the American Society of Hematology Annual Meeting held in December 2006 an interim analysis of the NCI's phase II study of romidepsin as a treatment for PTCL was presented. The interim results reported on 36 patients with PTCL. An overall response rate of 30% (11/36) was reported, with 3 complete responses (8%) and 8 partial responses (22%). The overall median duration of response has not yet been reached but was reported as being greater than 12 months. The most common adverse events reported were fatigue, nausea, and vomiting.

About Fast Track
'"/>




Page: 1 2 3

Related medicine technology :

1. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
2. Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting
3. Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:8/31/2015)... , Aug. 31, 2015  QT Vascular Ltd., together with ... together with its subsidiaries, the "Group"), a global ... of advanced therapeutic solutions for the minimally invasive ... results of the below-the-knee ("BTK") cohort of patients ... were presented on August 15, 2015 at the ...
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 ... the addition of the "Prescription Pain Drugs ... Medical Marijuana - Global Markets, Competitors and Opportunities: ... to their offering. Pain is ... associated with actual or potential tissue damage. At ...
(Date:8/29/2015)... y LONDRES, August 29, 2015 ... para los sistemas de imagen por Ultrasonidos ... Ecografía, tiempos de examen rápidos y un flujo de ... confianza diagnóstica en el proceso de detección de Cardiopatías ... PHIA) ha anunciado hoy el lanzamiento europeo de ...
Breaking Medicine Technology:Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5
... Estradiol Shown to Be Safe and Effective for Menopausal ... ... 3 A study presented today,at the 2007 Annual Meeting of the ... the,frequency and severity of moderate to severe hot flashes associated with,menopause. Additional ...
... Oct. 2 Medical Services,International Inc. (Pink Sheets: MSITF) ... Dengue Fever Kit is increasing. Dengue Fever is,spreading across ... worst,outbreaks in decades causing agonizing joint pain for hundreds ... this year. This year so far 630,356 cases ...
Cached Medicine Technology:New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes 2Demand for VScan Dengue Fever Test Kits Increases 2
(Date:8/31/2015)... ... 2015 , ... Since 1946, the doctors and staff at Clifton Dental Associates ... patient arrives at the office, the staff will make them feel welcome and comfortable. ... to create a complete dental treatment plan that is unique to each smile! ...
(Date:8/31/2015)... PLAINSBORO, N.J. (PRWEB) , ... August 31, 2015 ... ... its participants—physicians, drug makers, diagnostic services, and others—to hold down costs? , In ... MD, chief executive officer of HealthReveal, presents the concept of “clinical efficacy,” which ...
(Date:8/31/2015)... ... ... Three Bakers Gluten Free Bakery launched the redesign of its website, http://www.threebakers.com ... their offering of gluten-free breads and pizzas, living without gluten, and resources for celiac ... share information about our gluten free product offerings, but also to really be a ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... the CME-certified annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® ... Nov. 4 – 6 in New York City. The annual legacy meeting uses ...
(Date:8/31/2015)... ... 2015 , ... With baseball season in full swing, many fans are already ... sports world. Fans desire nothing more than to see their favorite team take the ... those who are too young to really understand what all the fuss is about, ...
Breaking Medicine News(10 mins):Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2
... Patients with symptomatic moderate asthma who were treated ... antibody, experienced significantly// fewer disease exacerbations than individuals ... the first issue for October 2006 of the ... published by the American Thoracic Society. ...
... in seven women will develop breast cancer in her life. ... disease? // ,Breast cancer specialists from the University of ... more anxiety than necessary. And in some cases the fear ... could lead to successful treatment. ,Here, experts debunk ...
... big time killer AIDS/ HIV infection worldwide Center for ... Benigno Rodriguez M.D and his extensive team of experts ... latest findings in the current issue of Journal Of ... by the latest findings, which contest that the measurement ...
... A recent study reveals that kids attending Montessori schools ... to academic and social development. However, an early education ... be conclusive.// ,In this study, thirty 5-year ... a public inner-city Montessori school in Milwaukee, Wis. were ...
... child’s death due to Japanese encephalitis, the death toll ... district.// ,According to the Additional Director (Health) ... have been reported from several parts of the district ... 74 people were undergoing treatment at the BRD Medical ...
... laws, which require minors to seek parental consent before ... this segment of the society. Jonathan Klick, the Jeffrey ... of economics at George Mason University examined the prevailing ... consent may play an important role. ,The ...
Cached Medicine News:Health News:Monoclonal Antibody Reduces Exacerbations in Asthmatics 2Health News:16 Common Myths About Breast Cancer 2Health News:16 Common Myths About Breast Cancer 3Health News:16 Common Myths About Breast Cancer 4Health News:16 Common Myths About Breast Cancer 5Health News:Montessori Schools kids do better in Reading and Math 2Health News:Laws That Make Parental Consent Mandatory Reduce Risky Sexual Behavior 2
Inquire...
Remote Blower With Bag-In/Bag-Out Option...
Bench Top Class I Containment Cabinet Personnel Protection...
Calss II Type B2 Biological Safety Cabinet...
Medicine Products: